SG11201702295UA - Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 - Google Patents

Improved therapeutic control of heterodimeric and single chain forms of interleukin-12

Info

Publication number
SG11201702295UA
SG11201702295UA SG11201702295UA SG11201702295UA SG11201702295UA SG 11201702295U A SG11201702295U A SG 11201702295UA SG 11201702295U A SG11201702295U A SG 11201702295UA SG 11201702295U A SG11201702295U A SG 11201702295UA SG 11201702295U A SG11201702295U A SG 11201702295UA
Authority
SG
Singapore
Prior art keywords
heterodimeric
interleukin
single chain
improved therapeutic
chain forms
Prior art date
Application number
SG11201702295UA
Inventor
Charles C Reed
Gregory Ian Frost
Joan Mazzarelli Sopczynski
Chi Zhang
Original Assignee
Intrexon Corp
Charles C Reed
Gregory Ian Frost
Joan Mazzarelli Sopczynski
Chi Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp, Charles C Reed, Gregory Ian Frost, Joan Mazzarelli Sopczynski, Chi Zhang filed Critical Intrexon Corp
Publication of SG11201702295UA publication Critical patent/SG11201702295UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SG11201702295UA 2014-09-22 2015-09-21 Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 SG11201702295UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053628P 2014-09-22 2014-09-22
US201462074875P 2014-11-04 2014-11-04
PCT/US2015/051246 WO2016048903A1 (en) 2014-09-22 2015-09-21 Improved therapeutic control of heterodimeric and single chain forms of interleukin-12

Publications (1)

Publication Number Publication Date
SG11201702295UA true SG11201702295UA (en) 2017-04-27

Family

ID=55581867

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702295UA SG11201702295UA (en) 2014-09-22 2015-09-21 Improved therapeutic control of heterodimeric and single chain forms of interleukin-12

Country Status (7)

Country Link
US (1) US20170291934A1 (en)
EP (1) EP3197911A4 (en)
AU (1) AU2015321603A1 (en)
CA (1) CA2962099A1 (en)
IL (1) IL251326A0 (en)
SG (1) SG11201702295UA (en)
WO (1) WO2016048903A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20135924B (en) 2005-12-02 2013-10-10 The Mount Sinai School Of Medicine Of New York Univ Chimeric viruses presenting non-native surface proteins and usage thereof
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
EP3441084A1 (en) 2014-02-27 2019-02-13 Viralytics Limited Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer
JP6912384B2 (en) 2015-04-22 2021-08-04 キュアバック アーゲー RNA-containing compositions for the treatment of cancer diseases
CN106520778A (en) * 2015-09-09 2017-03-22 北京锤特生物科技有限公司 Modified interleukin 12 and purpose of modified interleukin 12 in preparation of medicine for treating tumour
WO2017062953A1 (en) 2015-10-10 2017-04-13 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
EA201890861A1 (en) 2015-11-09 2018-10-31 Иммьюн Дизайн Корп. COMPOSITIONS, CONTAINING LENTIVIRUS VECTORS, EXPRESSING IL-12, AND METHODS OF THEIR APPLICATION
KR102469450B1 (en) 2016-05-18 2022-11-22 모더나티엑스, 인크. Polynucleotides Encoding Interleukin-12 (IL12) and Uses Thereof
CN110267978A (en) * 2016-10-07 2019-09-20 得克萨斯大学体系董事会 The T cell of the IL-12 of expression film anchoring for treating cancer
CN108147990B (en) * 2016-12-02 2023-01-24 上海中医药大学 Membrane anchoring element and application thereof
SG11201906213UA (en) 2017-01-10 2019-08-27 Intrexon Corp Modulating expression of polypeptides via new gene switch expression systems
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN110770249B (en) * 2017-04-21 2024-03-29 英特瑞克斯顿股份有限公司 Delivery of autologous cells comprising matrix metalloproteinases for the treatment of scleroderma
JOP20190256A1 (en) * 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
WO2018213731A1 (en) * 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
IL270990B2 (en) 2017-06-07 2024-02-01 Precigen Inc Expression of novel cell tags
MX2019014960A (en) 2017-06-12 2020-08-06 Obsidian Therapeutics Inc Pde5 compositions and methods for immunotherapy.
EP3648786A4 (en) 2017-07-03 2021-12-15 Torque Therapeutics, Inc. Fusion molecules targeting immune regulatory cells and uses thereof
CA3092935A1 (en) 2018-03-06 2019-09-12 Precigen, Inc. Hepatitis b vaccines and uses of the same
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20230081530A1 (en) * 2018-09-14 2023-03-16 Modernatx, Inc. Methods and compositions for treating cancer using mrna therapeutics
JP2022503959A (en) 2018-10-03 2022-01-12 ゼンコア インコーポレイテッド IL-12 heterodimer FC-fusion protein
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020123716A1 (en) 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
TW202045533A (en) * 2019-02-01 2020-12-16 美國德州系統大學評議委員會 Modified il-12 t cell therapy for the treatment of cancer
US20220267398A1 (en) 2019-06-12 2022-08-25 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
US20230002465A1 (en) * 2019-11-20 2023-01-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccinia viruses and methods for using vaccinia viruses
US20230399370A1 (en) * 2019-11-22 2023-12-14 Alaunos Therapeutics, Inc. Methods of treating glioblastoma
KR20230004646A (en) * 2020-04-17 2023-01-06 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Engineered IL-12 and IL-23 Polypeptides and Uses Thereof
BR112022021828A2 (en) * 2020-04-30 2023-01-17 Vlp Therapeutics Inc CYTOKINE IMMUNOTHERAPY
KR20240037185A (en) 2021-04-19 2024-03-21 이오반스 바이오테라퓨틱스, 인크. Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017689A2 (en) * 1996-10-18 1998-04-30 Valentis Inc. Il-12 gene expression and delivery systems and uses
GB9810999D0 (en) * 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
ES2272448T3 (en) * 2000-03-15 2007-05-01 Genexine Co., Ltd. GENES OF THE IL-12P40 MUNATE SUBUNITY TO IMPROVE THE ACTIVITY OF IL-12 AND USE OF THEMSELVES IN A GENETIC VACCINE COADYUVANT.
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
US20090142855A1 (en) * 2005-06-30 2009-06-04 Wei Tang Polynucleotides and Polypeptides of the IL-12 Family of Cytokines
EP3083666A4 (en) * 2013-12-18 2017-09-20 Intrexon Corporation Single chain il-12 nucleic acids, polypeptids, and uses thereof

Also Published As

Publication number Publication date
EP3197911A1 (en) 2017-08-02
EP3197911A4 (en) 2018-06-20
IL251326A0 (en) 2017-05-29
WO2016048903A1 (en) 2016-03-31
US20170291934A1 (en) 2017-10-12
AU2015321603A1 (en) 2017-04-13
CA2962099A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
IL251326A0 (en) Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
IL290488A (en) Therapeutic antibodies and their uses
IL258931A (en) Therapeutic compounds and methods
HK1247614A1 (en) Therapeutic compounds and uses thereof
HK1243073A1 (en) Therapeutic compounds and uses thereof
EP3377102C0 (en) Anti-pd-1 antibodies and therapeutic uses thereof
GB201403093D0 (en) Therapeutic compounds and their use
GB201404470D0 (en) Therapeutic methods and materials
HK1248697A1 (en) Therapeutic compounds and uses thereof
HK1247091A1 (en) Therapeutic antibodies and uses thereof
ZA201802256B (en) Compounds and therapeutic uses thereof
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
IL247325A0 (en) Therapeutic methods employing noribogaine and related compounds
IL270011B (en) Therapeutic compounds and methods
HK1258056A1 (en) Therapeutic compounds and methods of use thereof
IL258431A (en) Deimmunized therapeutic compositions and methods
ZA201703580B (en) Therapeutic homodimer and uses thereof
GB2533112B (en) Electroluminescent elements and methods of construction
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use